Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;20(4):450-463.
doi: 10.1007/s11102-017-0805-y.

Increased expression of the microRNA 106b~25 cluster and its host gene MCM7 in corticotroph pituitary adenomas is associated with tumor invasion and Crooke's cell morphology

Affiliations

Increased expression of the microRNA 106b~25 cluster and its host gene MCM7 in corticotroph pituitary adenomas is associated with tumor invasion and Crooke's cell morphology

Filip Garbicz et al. Pituitary. 2017 Aug.

Abstract

Purpose: MCM7 (minichromosome maintenance complex component 7), a DNA replication licensing factor, is a host gene for the oncogenic miR-106b~25 cluster. It has been recently revealed as a relevant prognostic biomarker in a variety of cancers, including pituitary adenomas. The purpose of this study was to assess whether miR-106b~25 and MCM7 levels correlate with tumor invasiveness in a cohort of ACTH-immunopositive adenomas.

Methods: Tissue samples were obtained intraoperatively from 25 patients with pituitary adenoma. Tumor invasiveness was assessed according to the Knosp grading scale. MCM7, Ki-67 and TP53 levels were assessed by immunohistochemical staining, while the expression of miR-106b-5p, miR-93-5p, miR-93-3p and miR-25-3p were measured using quantitative real-time PCR performed on RNA isolated from FFPE tissues.

Results: We have found a significant increase in MCM7 and Ki-67 labeling indices in invasive ACTHomas. Moreover, MCM7 was ubiquitously overexpressed in Crooke's cell adenomas. The expression of miR-93-5p was significantly elevated in invasive compared to noninvasive tumors. In addition, all four microRNAs from the miR-106b~25 cluster displayed marked upregulation in Crooke's cell adenomas. Remarkably, MCM7 and miR-106b-5p both strongly correlated with Knosp grade. A combination of MCM7 LI and miR-106b~25 cluster expression was able to accurately differentiate invasive from noninvasive tumors and had a significant discriminatory ability to predict postoperative tumor recurrence/progression.

Conclusions: miR-106b~25 and its host gene MCM7 are potential novel biomarkers for invasive ACTH-immunopositive pituitary adenomas. Additionally, they are both significantly upregulated in rare Crooke's cell adenomas and might therefore contribute to their aggressive phenotype.

Keywords: ACTHoma; Crooke’s cell adenoma; MCM7; MiR-106b~25 cluster; MicroRNA; Pituitary adenoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Pituitary corticotroph adenomas. a Ultrastructural features of densely granulated corticotroph adenoma: well-developed organelles, numerous, variable in shape, and electron dense secretory granules. Original magnification ×7400. b Electron microscopy of sparsely granulated corticotroph adenoma: small and scanty secretory granules. Original magnification ×9700. c H&E staining of Crooke’s cell adenoma (×200). d Ultrastructural features of Crooke’s cell adenoma: excessive accumulation of perinuclear cytokeratin filaments. Original magnification ×9700
Fig. 2
Fig. 2
A schematic representation of the polycistronic miR-106b~25 cluster and its host gene MCM7, located on chromosome 7q22
Fig. 3
Fig. 3
Immunohistochemical analysis of MCM7 expression in ACTH-producing pituitary adenoma samples. Presented are representative cases of MCM7-stained Crooke’s cell (a—2, b—3b), invasive (c—6, d—7a) and noninvasive (e—20, f—22) PAs. MCM7 (g) and Ki-67 (h) LIs are presented as % of positively stained cells in examined PAs. Columns represent means ± SEM. The subgroups were compared using the two-sided Mann–Whitney test: *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 4
Fig. 4
The elements of the miR-106b~25 cluster are coexpressed and upregulated in Crooke’s cell and invasive adenomas. ad The expression of miR-106b~25 cluster elements in three subgroups of PAs was compared using the two-sided Mann–Whitney test: *p < 0.05, **p < 0.01, ***p < 0.001. e The table presents Pearson correlation coefficients between the expression levels of microRNAs studied. All miRNAs are significantly coexpressed in PAs (p < 0.0001 for all coefficients)
Fig. 5
Fig. 5
MCM7 and miR-106b-5p are coexpressed in ACTHomas. ad The correlation was calculated using Pearson’s coefficient
Fig. 6
Fig. 6
The expression of miR-106b-5p and MCM7 LI correlates with tumor’s Knosp grade. Scatter plots showing the relationship between tumor’s Knosp grade and miR-106b~25 expression (ad) as well as MCM7 LI (e). Correlation was characterized by calculating Spearman’s rank coefficient
Fig. 7
Fig. 7
MCM7 LI in combination with the expression of miR-106b~25 is a specific and sensitive test discriminating invasive from noninvasive ACTHomas. a In order to establish the role of the IHC biomarkers and microRNAs studied, we analyzed the area under the receiver operating characteristic (AUC ROC). b A graphical representation of the three top AUC values
Fig. 8
Fig. 8
Performance of MCM7 LI, miR-106b~25 expression and Ki67 LI in identifying patients with unfavorable prognosis. a A summary of AUC ROC calculated for progression/recurrence and post-operative residual tumor accompanied by a graphical representation of those values (b, c). d The expression of MCM7 in residual tumors that progressed or remained stable calculated using the two-sided Mann–Whitney test: *p < 0.05

Similar articles

Cited by

References

    1. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011;7:257–266. doi: 10.1038/nrendo.2011.40. - DOI - PubMed
    1. Cooper O, Melmed S. Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab. 2012;26:447–460. doi: 10.1016/j.beem.2012.01.002. - DOI - PMC - PubMed
    1. Nieman LK, Ilias I. Evaluation and treatment of Cushing’s syndrome. Am J Med. 2005;118:1340–1346. doi: 10.1016/j.amjmed.2005.01.059. - DOI - PubMed
    1. Seltzer J, Ashton CE, Scotton TC, et al. Gene and protein expression in pituitary corticotroph adenomas: a systematic review of the literature. Neurosurg Focus. 2015;38:E17. doi: 10.3171/2014.10.FOCUS14683. - DOI - PubMed
    1. Syro LV, Rotondo F, Cusimano MD, et al. Current status on histological classification in Cushing’s disease. Pituitary. 2015;18:217–224. doi: 10.1007/s11102-014-0619-0. - DOI - PubMed

Substances